Advertisement
Review Article| Volume 39, ISSUE 1, P15-29, March 2019

Regulatory and Effector B Cells: A New Path Toward Biomarkers and Therapeutic Targets to Improve Transplant Outcomes?

  • Aravind Cherukuri
    Affiliations
    Section of Nephrology, Department of Medicine, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, W1545 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Search for articles by this author
  • Qing Ding
    Affiliations
    Department of Surgery, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, W1545 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Search for articles by this author
  • Akhil Sharma
    Affiliations
    Section of Nephrology, Department of Medicine, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, W1545 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Search for articles by this author
  • Kanishka Mohib
    Affiliations
    Department of Surgery, University of Pittsburgh, Thomas E. Starzl Transplantation Institute, University of Pittsburgh School of Medicine, 200 Lothrop Street, W1545 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Search for articles by this author
  • David M. Rothstein
    Correspondence
    Corresponding author.
    Affiliations
    Departments of Surgery, Medicine and Immunology, Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, W1545 Biomedical Science Tower, Pittsburgh, PA 15261, USA
    Search for articles by this author
Published:December 17, 2018DOI:https://doi.org/10.1016/j.cll.2018.10.011

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mauri C.
        • Menon M.
        The expanding family of regulatory B cells.
        Int Immunol. 2015; 27: 479-486
        • Shen P.
        • Fillatreau S.
        Antibody-independent functions of B cells: a focus on cytokines.
        Nat Rev Immunol. 2015; 15: 441-451
        • Lund F.E.
        • Randall T.D.
        Effector and regulatory B cells: modulators of CD4+ T cell immunity.
        Nat Rev Immunol. 2010; 10: 236-247
        • Fillatreau S.
        Pathogenic functions of B cells in autoimmune diseases: IFN-gamma production joins the criminal gang.
        Eur J Immunol. 2015; 45: 966-970
        • Bao Y.
        • Liu X.
        • Han C.
        • et al.
        Identification of IFN-γ-producing innate B cells.
        Cell Res. 2014; 24: 161-176
        • Ding Q.
        • Yeung M.
        • Camirand G.
        • et al.
        Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice.
        J Clin Invest. 2011; 121: 3645-3656
        • Balkwill F.
        • Montfort A.
        • Capasso M.
        B regulatory cells in cancer.
        Trends Immunol. 2013; 34: 169-173
        • Iwata Y.
        • Matsushita T.
        • Horikawa M.
        • et al.
        Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.
        Blood. 2011; 117: 530-541
        • Newell K.A.
        • Asare A.
        • Kirk A.D.
        • et al.
        Identification of a B cell signature associated with renal transplant tolerance in humans.
        J Clin Invest. 2010; 120: 1836-1847
        • Sagoo P.
        • Perucha E.
        • Sawitzki B.
        • et al.
        Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.
        J Clin Invest. 2010; 120: 1848-1861
        • Cherukuri A.
        • Rothstein D.M.
        • Clark B.
        • et al.
        Immunologic human renal allograft injury associates with an altered IL-10/TNF-α expression ratio in regulatory B cells.
        J Am Soc Nephrol. 2014; 25: 1575-1585
        • Chesneau M.
        • Michel L.
        • Dugast E.
        • et al.
        Tolerant kidney transplant patients produce B cells with regulatory properties.
        J Am Soc Nephrol. 2015; 26: 2588-2598
        • Pallier A.
        • Hillion S.
        • Danger R.
        • et al.
        Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype.
        Kidney Int. 2010; 78: 503-513
        • Menon M.
        • Blair P.A.
        • Isenberg D.A.
        • et al.
        A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus.
        Immunity. 2016; 44: 683-697
        • Noh J.
        • Lee J.H.
        • Noh G.
        • et al.
        Characterisation of allergen-specific responses of IL-10-producing regulatory B cells (Br1) in Cow Milk Allergy.
        Cell Immunol. 2010; 264: 143-149
        • Siewe B.
        • Stapleton J.T.
        • Martinson J.
        • et al.
        Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8+ T cell function in vitro.
        J Leukoc Biol. 2013; 93: 811-818
        • Blair P.A.
        • Noreña L.Y.
        • Flores-Borja F.
        • et al.
        CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.
        Immunity. 2010; 32: 129-140
        • Lino A.C.
        • Dorner T.
        • Bar-Or A.
        • et al.
        Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.
        Immunol Rev. 2016; 269: 130-144
        • Barr T.A.
        • Brown S.
        • Mastroeni P.
        • et al.
        TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica.
        J Immunol. 2010; 185: 2783-2789
        • Olalekan S.A.
        • Cao Y.
        • Hamel K.M.
        • et al.
        B cells expressing IFN-gamma suppress Treg-cell differentiation and promote autoimmune experimental arthritis.
        Eur J Immunol. 2015; 45: 988-998
        • Roll P.
        • Dorner T.
        • Tony H.P.
        Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
        Arthritis Rheum. 2008; 58: 1566-1575
        • Cambridge G.
        • Perry H.C.
        • Nogueira L.
        • et al.
        The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.
        J Autoimmun. 2014; 50: 67-76
        • Martin F.
        • Chan A.C.
        B cell immunobiology in disease: evolving concepts from the clinic.
        Annu Rev Immunol. 2006; 24: 467-496
        • Hu C.Y.
        • Rodriguez-Pinto D.
        • Du W.
        • et al.
        Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.
        J Clin Invest. 2007; 117: 3857-3867
        • Edwards J.C.
        • Szczepanski L.
        • Szechinski J.
        • et al.
        Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
        N Engl J Med. 2004; 350: 2572-2581
        • Bouaziz J.D.
        • Yanaba K.
        • Venturi G.M.
        • et al.
        Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.
        Proc Natl Acad Sci U S A. 2007; 104: 20878-20883
        • Matsushita T.
        • Yanaba K.
        • Bouaziz J.D.
        • et al.
        Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.
        J Clin Invest. 2008; 118: 3420-3430
        • Kappos L.
        • Hartung H.P.
        • Freedman M.S.
        • et al.
        Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
        Lancet Neurol. 2014; 13: 353-363
        • Thaunat O.
        • Morelon E.
        • Defrance T.
        Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis.
        Blood. 2010; 116: 515-521
        • Bouaziz J.D.
        • Yanaba K.
        • Tedder T.F.
        Regulatory B cells as inhibitors of immune responses and inflammation.
        Immunol Rev. 2008; 224: 201-214
        • Clatworthy M.R.
        • Watson C.J.
        • Plotnek G.
        • et al.
        B-cell-depleting induction therapy and acute cellular rejection.
        N Engl J Med. 2009; 360: 2683-2685
        • Watanabe R.
        • Fujimoto M.
        • Ishiura N.
        • et al.
        CD19 expression in B cells is important for suppression of contact hypersensitivity.
        Am J Pathol. 2007; 171: 560-570
        • Mizoguchi A.
        • Mizoguchi E.
        • Takedatsu H.
        • et al.
        Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation.
        Immunity. 2002; 16: 219-230
        • Fillatreau S.
        • Sweenie C.H.
        • McGeachy M.J.
        • et al.
        B cells regulate autoimmunity by provision of IL-10.
        Nat Immunol. 2002; 3: 944-950
        • Yanaba K.
        • Bouaziz J.D.
        • Haas K.M.
        • et al.
        A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses.
        Immunity. 2008; 28: 639-650
        • Shah S.
        • Divekar A.A.
        • Hilchey S.P.
        • et al.
        Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.
        Int J Cancer. 2005; 117: 574-586
        • Qin Z.
        • Richter G.
        • Schüler T.
        • et al.
        B cells inhibit induction of T cell-dependent tumor immunity.
        Nat Med. 1998; 4: 627-630
        • DiLillo D.J.
        • Yanaba K.
        • Tedder T.F.
        B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice.
        J Immunol. 2010; 184: 4006-4016
        • Schultz K.R.
        • Klarnet J.P.
        • Gieni R.S.
        • et al.
        The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia.
        Science. 1990; 249: 921-923
        • Nelson B.H.
        CD20+ B cells: the other tumor-infiltrating lymphocytes.
        J Immunol. 2010; 185: 4977-4982
        • Bar-Or A.
        • Fawaz L.
        • Fan B.
        • et al.
        Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?.
        Ann Neurol. 2010; 67: 452-461
        • Cherukuri A.
        • Salama A.D.
        • Carter C.R.
        • et al.
        Human transitional B cell T1/T2 ratio is a new marker for allograft deteriotration in kidney transplant recipients.
        Kidney Int. 2017; 91 (*denotes equal contribution): 183-195
        • Blair P.A.
        • Chavez-Rueda K.A.
        • Evans J.G.
        • et al.
        Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice.
        J Immunol. 2009; 182: 3492-3502
        • Sun J.
        • Wang J.
        • Pefanis E.
        • et al.
        Transcriptomics identify CD9 as a marker of murine IL-10-competent regulatory B cells.
        Cell Rep. 2015; 13: 1110-1117
        • Ding Q.
        • Mohib K.
        • Kuchroo V.K.
        • et al.
        TIM-4 identifies IFN-gamma-expressing proinflammatory B effector 1 cells that promote tumor and allograft rejection.
        J Immunol. 2017; 199: 2585-2595
        • Xiao S.
        • Brooks C.R.
        • Sobel R.A.
        • et al.
        Tim-1 is essential for induction and maintenance of IL-10 in regulatory B cells and their regulation of tissue inflammation.
        J Immunol. 2015; 194: 1602-1608
        • Yeung M.Y.
        • Ding Q.
        • Brooks C.R.
        • et al.
        TIM-1 signaling is required for maintenance and induction of regulatory B cells.
        Am J Transplant. 2015; 15: 942-953
        • Matsumoto M.
        • Baba A.
        • Yokota T.
        • et al.
        Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation.
        Immunity. 2014; 41: 1040-1051
        • Shen P.
        • Roch T.
        • Lampropoulou V.
        • et al.
        IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases.
        Nature. 2014; 507: 366-370
        • Harris D.P.
        • Goodrich S.
        • Gerth A.J.
        • et al.
        Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor.
        J Immunol. 2005; 174: 6781-6790
        • Bermejo D.A.
        • Jackson S.W.
        • Gorosito-Serran M.
        • et al.
        Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells.
        Nat Immunol. 2013; 14: 514-522
        • Wojciechowski W.
        • Harris D.P.
        • Sprague F.
        • et al.
        Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus.
        Immunity. 2009; 30: 421-433
        • Barr T.A.
        • Shen P.
        • Brown S.
        • et al.
        B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.
        J Exp Med. 2012; 209: 1001-1010
        • Zeng Q.
        • Ng Y.H.
        • Singh T.
        • et al.
        B cells mediate chronic allograft rejection independently of antibody production.
        J Clin Invest. 2014; 124: 1052-1056
        • Mauri C.
        • Menon M.
        Human regulatory B cells in health and disease: therapeutic potential.
        J Clin Invest. 2017; 127: 772-779
        • van de Veen W.
        • Stanic B.
        • Yaman G.
        • et al.
        IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.
        J Allergy Clin Immunol. 2013; 131: 1204-1212
        • Aravena O.
        • Ferrier A.
        • Menon M.
        • et al.
        TIM-1 defines a human regulatory B cell population that is altered in frequency and function in systemic sclerosis patients.
        Arthritis Res Ther. 2017; 19: 8
        • Ticha O.
        • Moos L.
        • Wajant H.
        • et al.
        Expression of tumor necrosis factor receptor 2 characterizes TLR9-driven formation of interleukin-10-producing B cells.
        Front Immunol. 2017; 8: 1951
        • Griffin D.O.
        • Rothstein T.L.
        Human "orchestrator" CD11b(+) B1 cells spontaneously secrete interleukin-10 and regulate T-cell activity.
        Mol Med. 2012; 18: 1003-1008
        • Chesneau M.
        • Pallier A.
        • Braza F.
        • et al.
        Unique B cell differentiation profile in tolerant kidney transplant patients.
        Am J Transplant. 2014; 14: 144-155
        • Nova-Lamperti E.
        • Fanelli G.
        • Becker P.D.
        • et al.
        IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4+T-cell responses.
        Sci Rep. 2016; 6: 20044
        • Nova-Lamperti E.
        • Chana P.
        • Mobillo P.
        • et al.
        Increased CD40 ligation and reduced BCR signalling leads to higher IL-10 production in B cells from tolerant kidney transplant patients.
        Transplantation. 2017; 101: 541-547
        • Newell K.A.
        • Asare A.
        • Sanz I.
        • et al.
        Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients.
        Am J Transplant. 2015; 15: 2908-2920
        • Rebollo-Mesa I.
        • Nova-Lamperti E.
        • Mobillo P.
        • et al.
        Biomarkers of tolerance in kidney transplantation: are we predicting tolerance or response to immunosuppressive treatment?.
        Am J Transplant. 2016; 16: 3443-3457
        • Markmann J.F.
        Signatures of tolerance or immunosuppression?.
        Am J Transplant. 2016; 16: 3320-3321
        • Vidic A.S.
        • Edwards R.
        • Toll L.B.
        • et al.
        Rituximab induction and risk of cardiac allograft vasculopathy, rejection and death.
        J Heart Lung Transplant. 2017; 36: S88
        • Vo A.A.
        • Lukovsky M.
        • Toyoda M.
        • et al.
        Rituximab and intravenous immune globulin for desensitization during renal transplantation.
        N Engl J Med. 2008; 359: 242-251
        • Kopchaliiska D.
        • Zachary A.A.
        • Montgomery R.A.
        • et al.
        Reconstitution of peripheral allospecific CD19+ B-cell subsets after B-lymphocyte depletion therapy in renal transplant patients.
        Transplantation. 2009; 87: 1394-1401
        • Tebbe B.
        • Wilde B.
        • Ye Z.
        • et al.
        Renal transplant recipients treated with calcineurin-inhibitors lack circulating immature transitional CD19+CD24hiCD38hi regulatory B-lymphocytes.
        PLoS One. 2016; 11: e0153170
        • Shabir S.
        • Girdlestone J.
        • Briggs D.
        • et al.
        Transitional B lymphocytes are associated with protection from kidney allograft rejection: a prospective study.
        Am J Transplant. 2015; 15: 1384-1391
        • Svachova V.
        • Sekerkova A.
        • Hruba P.
        • et al.
        Dynamic changes of B-cell compartments in kidney transplantation: lack of transitional B cells is associated with allograft rejection.
        Transpl Int. 2016; 29: 540-548
        • Cherukuri A.
        • Salama A.D.
        • Carter C.
        • et al.
        An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation.
        Am J Transplant. 2012; 12: 919-931
        • Schlosser H.A.
        • Thelen M.
        • Dieplinger G.
        • et al.
        Prospective analyses of circulating B cell subsets in ABO-compatible and ABO-incompatible kidney transplant recipients.
        Am J Transplant. 2017; 17: 542-550
        • Nouël A.
        • Ségalen I.
        • Jamin C.
        • et al.
        B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection.
        Kidney Int. 2014; 85: 590-599
        • Cherukuri A.
        • Salama A.D.
        • Carter C.R.
        • et al.
        Reduced human transitional B cell T1/T2 ratio is associated with subsequent deterioration in renal allograft function.
        Kidney Int. 2017; 91: 183-195
        • Khoder A.
        • Sarvaria A.
        • Alsuliman A.
        • et al.
        Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.
        Blood. 2014; 124: 2034-2045
        • Sarvaria A.
        • Basar R.
        • Mehta R.S.
        • et al.
        IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.
        Blood. 2016; 128: 1346-1361
        • Heidt S.
        • Hester J.
        • Shankar S.
        • et al.
        B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naive B cells.
        Am J Transplant. 2012; 12: 1784-1792
        • Todeschini M.
        • Cortinovis M.
        • Perico N.
        • et al.
        In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.
        J Immunol. 2013; 191: 2818-2828
        • Toso C.
        • Edgar R.
        • Pawlick R.
        • et al.
        Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation.
        Transpl Int. 2009; 22: 182-191
        • Kho M.M.
        • Bouvy A.P.
        • Cadogan M.
        • et al.
        The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients.
        Transpl Immunol. 2012; 26: 186-190
        • Zand M.S.
        • Vo T.
        • Huggins J.
        • et al.
        Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways.
        Transplantation. 2005; 79: 1507-1515
        • Longshan L.
        • Dongwei L.
        • Qian F.
        • et al.
        Dynamic analysis of B-cell subsets in de novo living related kidney transplantation with induction therapy of basiliximab.
        Transplant Proc. 2014; 46: 363-367
        • Kamburova E.G.
        • Koenen H.J.
        • Boon L.
        • et al.
        In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.
        Am J Transplant. 2012; 12: 341-350
        • Kovacs W.J.
        To B or not to B? Glucocorticoid impact on B lymphocyte fate and function.
        Endocrinology. 2014; 155: 339-342
        • Grayson J.
        • Dooley N.J.
        • Koski I.R.
        • et al.
        Immunoglobulin production induced in vitro by glucocorticoid hormones: T cell-dependent stimulation of immunoglobulin production without B cell proliferation in cultures of human peripheral blood lymphocytes.
        J Clin Invest. 1981; 68: 1539-1547
        • Fauci A.S.
        • Pratt K.R.
        • Whalen G.
        Activation of human B lymphocytes. IV. Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes to polyclonal activation.
        J Immunol. 1977; 119: 598-603
        • Matz M.
        • Lehnert M.
        • Lorkowski C.
        • et al.
        Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.
        Transpl Int. 2012; 25: 1106-1116
        • Joly M.S.
        • Martin R.P.
        • Mitra-Kaushik S.
        • et al.
        Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa.
        J Immunol. 2014; 193: 3947-3958
        • Latorre I.
        • Esteve-Sole A.
        • Redondo D.
        • et al.
        Calcineurin and mTOR inhibitors have opposing effects on regulatory T cells while reducing regulatory B cell populations in kidney transplant recipients.
        Transpl Immunol. 2016; 35: 1-6
        • Leibler C.
        • Matignon M.
        • Pilon C.
        • et al.
        Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells.
        Am J Transplant. 2014; 14: 1173-1182
        • Furuzawa-Carballeda J.
        • Bostock I.C.
        • Lima G.
        • et al.
        Immunophenotyping of peripheral immunoregulatory as well as Th17A and Th22 cell subpopulations in kidney transplant recipients under belatacept or cyclosporine treatment.
        Transpl Immunol. 2014; 30: 107-113
        • Banham G.D.
        • Flint S.M.
        • Torpey N.
        • et al.
        Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.
        Lancet. 2018; https://doi.org/10.1016/S0140-6736(18)30984-X
        • Lee K.M.
        • Kim J.I.
        • Stott R.
        • et al.
        Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells.
        Am J Transplant. 2012; 12: 2072-2078
        • Gray M.
        • Miles K.
        • Salter D.
        • et al.
        Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells.
        Proc Natl Acad Sci U S A. 2007; 104: 14080-14085
        • Yanaba K.
        • Bouaziz J.D.
        • Matsushita T.
        • et al.
        The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals.
        J Immunol. 2009; 182: 7459-7472
        • Schubert R.D.
        • Hu Y.
        • Kumar G.
        • et al.
        IFN-β treatment requires B cells for efficacy in neuroautoimmunity.
        J Immunol. 2015; 194: 2110-2116
        • Toubi E.
        • Nussbaum S.
        • Staun-Ram E.
        • et al.
        Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.
        J Neuroimmunol. 2012; 251: 45-54
        • Grützke B.
        • Hucke S.
        • Gross C.C.
        • et al.
        Fingolimod treatment promotes regulatory phenotype and function of B cells.
        Ann Clin Transl Neurol. 2015; 2: 119-130
        • Snir A.
        • Kessel A.
        • Haj T.
        • et al.
        Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy.
        Clin Exp Rheumatol. 2011; 29: 697-700
        • Assier E.
        • Boissier M.C.
        • Dayer J.M.
        Interleukin-6: from identification of the cytokine to development of targeted treatments.
        Joint Bone Spine. 2010; 77: 532-536
        • Bankó Z.
        • Pozsgay J.
        • Gáti T.
        • et al.
        Regulatory B cells in rheumatoid arthritis: alterations in patients receiving anti-TNF therapy.
        Clin Immunol. 2017; 184: 63-69
        • Anolik J.H.
        • Ravikumar R.
        • Barnard J.
        • et al.
        Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks.
        J Immunol. 2008; 180: 688-692
        • Wang Q.T.
        • Wu Y.J.
        • Huang B.
        • et al.
        Etanercept attenuates collagen-induced arthritis by modulating the association between BAFFR expression and the production of splenic memory B cells.
        Pharmacol Res. 2013; 68: 38-45
        • Heine G.
        • Niesner U.
        • Chang H.D.
        • et al.
        1,25-dihydroxyvitamin D(3) promotes IL-10 production in human B cells.
        Eur J Immunol. 2008; 38: 2210-2218
        • Di Caro V.
        • Phillips B.
        • Engman C.
        • et al.
        Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice.
        PLoS One. 2014; 9: e83575
        • Rosser E.C.
        • Oleinika K.
        • Tonon S.
        • et al.
        Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.
        Nat Med. 2014; 20: 1334-1339
        • Wang R.X.
        • Yu C.R.
        • Dambuza I.M.
        • et al.
        Interleukin-35 induces regulatory B cells that suppress autoimmune disease.
        Nat Med. 2014; 20: 633-641
        • Yoshizaki A.
        • Miyagaki T.
        • DiLillo D.J.
        • et al.
        Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.
        Nature. 2012; 491: 264-268